49 completed, 29 unknown, 14 recruiting, 13 not yet recruiting. 129 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 129 | Completed 49, Unknown 29, Recruiting 14, Not yet recruiting 13, Active not recruiting 9, Terminated 7, Withdrawn 7, Suspended 1 |
Follow Liver Diseases: new trials by email Literature Review of Liver Diseases trials Research Report on Liver Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NK521 in the Treatment of Advanced Solid Tumors NK521 Cell Injection - Hepatocellular Carcinoma (HCC), Ovarian Cancer | Early Phase 1 | Not yet recruiting | Base Therapeutics (Shanghai) Co., Ltd. | 18 | 2027-01-01 | 2026-09-30 |
| GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer GLP1-RA (semaglutide) - Pancreatic Cancer, Colorectal Cancer | Early Phase 1 | Recruiting | University of Arizona | 30 | 2026-10-10 | 2026-09-18 |
| Silymarin Versus N-Acetylcysteine as Protective Effect Against Anti-tuberculosis Drugs Induced Liver Injury. Antituberculosis drugs Group - Drug-Induced Acute Liver Injury, Tuberculosis (TB) | Early Phase 1 | Not yet recruiting | Assiut University | 102 | 2026-10-01 | 2026-10-21 |
| THIO and Cadonilimab in Resectable Hepatocellular Carcinoma ateganosine, Cadonilimab - Resectable Hepatocellular Carcinoma | Early Phase 1 | Recruiting | University of Texas Southwestern Medical Center | 60 | 2026-09-01 | 2026-09-03 |
| Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer [64Cu]CM500, [68Ga]CM500, PET/MR - Bladder Cancer, Glioma | Early Phase 1 | Not yet recruiting | Lumina Pharmaceuticals Inc | 40 | 2026-09-01 | 2026-08-28 |
| Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection Autologous Cytokine-Induced Killer (CIK) Cells - Hepatocellular Carcinoma (HCC) | Early Phase 1 | Not yet recruiting | Royan Institute | 6 | 2026-07-01 | 2026-07-16 |
| Fecal Microbiota Transplantation for the Treatment of Refractory Hepatic Encephalopathy After TIPS Surgery Fecal Microbiota Transplantation, RifaximinăLactulose, Dietary Fiber Prebiotic - Hepatic Encephalopathy, Fecal Microbiota Transplantation | Early Phase 1 | Recruiting | Air Force Military Medical University, China | 26 | 2026-06-01 | 2026-07-06 |
| 5G Remote Robotic Surgery for Hepatic Echinococcosis in High-Altitude Region 5G-based Telerobotic Hepatectomy - Hepatic Echinococcosis | Early Phase 1 | Not yet recruiting | West China Hospital | 10 | 2026-05-01 | 2026-04-24 |
| Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection Peginterferon alfa-2b, TDF, TAF - Hepatocellular Carcinoma, HEPATITIS B CHRONIC | Early Phase 1 | Not yet recruiting | Ningbo No.2 Hospital | 156 | 2026-03-31 | 2026-04-28 |
| Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma Metabolically Armed GPC3 CAR-T cells - Hepatocellular Carcinoma (HCC) | Early Phase 1 | Not yet recruiting | Zhejiang University | 27 | 2026-03-30 | 2026-04-21 |
| A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects. Test drug XTYW007 capsules and placebo,Single dose group, Test drug XTYW007 capsules and placebo,Food Impact Group, Test drug XTYW007 capsules and placebo,Multiple dosing group - Non-Alcoholic Fatty Liver Disease | Early Phase 1 | Not yet recruiting | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 94 | 2026-03-25 | 2026-02-12 |
| Ex Vivo Perfusion of Gene-Edited Porcine Livers in Patients With Severe Hepatic Failure Ex vivo perfusion of six-gene-edited porcine liver, Multi-drug immunosuppressive therapy - Hepatic Failure | Early Phase 1 | Active not recruiting | Xijing Hospital | 1 | 2026-01-31 | 2026-04-09 |
| Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma 68Ga-XH06 - Malignant Neoplasm of Liver | Early Phase 1 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 150 | 2026-01-30 | 2026-01-20 |
| PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure exosome injection, standard comprehensive internal medical treatment, - Acute-on-Chronic Liver Failure (ACLF) | Early Phase 1 | Active not recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 20 | 2026-01-01 | 2026-02-13 |
| NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC ICG-Cisplatin Nanoprobe (NIR-II NanoM), Fluorescence-guided Hepatectomy - Liver Cancer, Adult | Early Phase 1 | Recruiting | West China Hospital | 30 | 2026-01-01 | 2025-12-19 |
| A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101) Group 1: DSL101 Low dose, Group 2: DSL101 Medium dose, Group 3: DSL101 High dose - Wilsons Disease | Early Phase 1 | Recruiting | DSciLab Co., Ltd. | 18 | 2025-12-31 | 2026-01-20 |
| The Improvement Effect of Henggliejin on Fatty Liver in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver: Addition of Hengge Liejing treatment for 48 weeks - NAFLD, Diabete Type 2 | Early Phase 1 | Not yet recruiting | Fujian Medical University Union Hospital | 149 | 2025-11-01 | 2025-09-30 |
| Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors Metabolically Armed TIL cells - Advanced Solid Tumors | Early Phase 1 | Recruiting | Anhui Provincial Hospital | 36 | 2025-08-29 | 2025-09-15 |
| Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) YOLT-202 - Alpha-1 Antitrypsin Deficiency (AATD) | Early Phase 1 | Active not recruiting | RenJi Hospital | 18 | 2025-06-18 | 2025-09-26 |
| Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC) Fenofibrate - Primary Biliary Cholangitis (PBC) | Early Phase 1 | Active not recruiting | Xijing Hospital of Digestive Diseases | 15 | 2025-03-13 | 2026-07-29 |
Showing 20 of 129. Sign in to see all of them.
Carcinoma, Hepatocellular (53) · Non-alcoholic Fatty Liver Disease (15) · Liver Neoplasms (13) · Liver Cirrhosis (8) · Fatty Liver (7) · Hepatitis B, Chronic (7) · Breast Neoplasms (6) · Colorectal Neoplasms (6) · Pancreatic Neoplasms (6) · Hepatitis C (5) · Carcinoma, Non-Small-Cell Lung (4) · Liver Cirrhosis, Biliary (4) · Lung Neoplasms (4) · Ovarian Neoplasms (4) · Sarcoma (4)
Digestive System Diseases (129) · Digestive System Neoplasms (61) · Neoplasms by Site (61) · Neoplasms (59) · Neoplasms by Histologic Type (56) · Neoplasms, Glandular and Epithelial (55) · Adenocarcinoma (53) · Carcinoma (52) · Liver Neoplasms (48) · Pathological Conditions, Signs and Symptoms (34) · Pathologic Processes (29) · Hepatitis (20) · Infections (19) · Virus Diseases (17)
Magnetic Resonance Spectroscopy (3) · lenvatinib (3) · 68Ga-DKFZ-PSMA-11 (2) · Biopsy (2) · Cyclophosphamide (2) · Fenofibrate (2) · Nivolumab (2) · Oncolytic Virotherapy (2) · Radiosurgery (2) · Sofosbuvir (2) · Sorafenib (2) · daclatasvir (2) · gallium 68 PSMA-11 (2) · pembrolizumab (2) · sofosbuvir-velpatasvir drug combination (2)
Beijing Ditan Hospital (5) · Massachusetts General Hospital (4) · Assiut University (3) · Mayo Clinic (3) · Northwestern University (3) · Third Affiliated Hospital, Sun Yat-Sen University (3) · Beijing 302 Hospital (2) · BioSyngen Pte Ltd (2) · First Affiliated Hospital Xi'an Jiaotong University (2) · Jonsson Comprehensive Cancer Center (2) · Shanghai Changzheng Hospital (2) · Shanghai Yunying Medical Technology (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · West China Hospital (2) · Active Genomes Expressed Diagnostics, Corp (1)
China (50) · United States (48) · Egypt (5) · United Kingdom (3) · Iran (2) · Taiwan (2) · Armenia (1) · Canada (1) · Denmark (1) · Finland (1) · India (1) · Singapore (1) · Sweden (1)
Wei-Fen Xie, M.D. (2) · Aaron J Scott, MD (1) · Abeer Esmat Abd El-Hamed, Lecturer (1) · Abeer Sharaf Abdel Rehim, Professor (1) · Adrian VS Hill, Prof (1) · Ahmed E Mohamed, Master (1) · Ajit H Goenka, MD (1) · Ajit H. Goenka, M.D. (1) · Ann Raldow, MD (1) · Anton Cheng, MBBS FRCS (1) · Ashu Rastogi, MD,DM (1) · Ashwin Somasundaram, MD (1) · Asmaa Mohammed Hussein, Assis.Prof (1) · Ayako Suzuki (1) · Ayman El Nakeeb, MD (1)
PMID 10898704, PMID 17635375, PMID 18639230, PMID 19095497, PMID 19109835, PMID 20335583, PMID 21157444, PMID 22298568, PMID 22370735, PMID 22454486, PMID 23993913, PMID 24696183, PMID 25027973, PMID 25060964, PMID 25309092, PMID 25819304, PMID 25948673, PMID 25997043, PMID 26084406, PMID 26674592, PMID 26966160, PMID 27512927, PMID 27918777, PMID 28249726, PMID 28902040, PMID 28994123, PMID 29471013, PMID 30207593, PMID 30220234, PMID 30959462, PMID 31063184, PMID 31070690, PMID 31096099, PMID 31172417, PMID 31579027, PMID 31606437, PMID 31652392, PMID 31988585, PMID 32004593, PMID 32278004, PMID 32497895, PMID 32717289, PMID 32781201, PMID 33365268, PMID 33385299, PMID 33421158, PMID 33721837, PMID 34006193, PMID 34256305, PMID 35220659
P30CA006973 (1), P30CA046934 (1), P30CA060553 (1), P30CA138292 (1), R01HL069877 (1), R44CA275590 (1)